Scholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Rating of “Buy” by Analysts

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have earned an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $40.43.

SRRK has been the subject of a number of recent analyst reports. Truist Financial lifted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. HC Wainwright lifted their price target on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Scholar Rock in a report on Wednesday, January 29th.

Insiders Place Their Bets

In other Scholar Rock news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the sale, the insider now owns 10,850,005 shares of the company’s stock, valued at $417,616,692.45. This trade represents a 3.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jay T. Backstrom sold 22,308 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $986,013.60. Following the completion of the transaction, the chief executive officer now directly owns 330,363 shares in the company, valued at approximately $14,602,044.60. This trade represents a 6.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 559,407 shares of company stock valued at $21,686,786 in the last ninety days. 19.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp purchased a new position in Scholar Rock during the fourth quarter worth about $212,000. GF Fund Management CO. LTD. acquired a new position in shares of Scholar Rock in the 4th quarter worth approximately $85,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Scholar Rock during the 4th quarter worth approximately $16,680,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Scholar Rock by 42.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company’s stock valued at $5,845,000 after purchasing an additional 40,436 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its position in Scholar Rock by 317.4% in the fourth quarter. Voloridge Investment Management LLC now owns 201,576 shares of the company’s stock valued at $8,712,000 after purchasing an additional 153,280 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $39.15 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The company has a 50 day moving average price of $41.89 and a 200-day moving average price of $28.17. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -16.66 and a beta of 0.50.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.